Last reviewed · How we verify

Meperidine, Midazolam

University of California, Irvine · FDA-approved active Small molecule ✓ Verified Jun 2026 Quality 5/100

Meperidine, Midazolam is a Small molecule drug developed by University of California, Irvine. It is currently FDA-approved.

Meperidine is a medication used to treat pain, and its exact mechanism of action is not specified in the provided facts. Midazolam is a small molecule that acts as a positive allosteric modulator of the GABA-A receptor and anion channel, and it is used to treat conditions such as anxiety and pain, as well as for procedural sedation during medical procedures like colonoscopy.

At a glance

Generic nameMeperidine, Midazolam
SponsorUniversity of California, Irvine
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Meperidine, Midazolam

What is Meperidine, Midazolam?

Meperidine, Midazolam is a Small molecule drug developed by University of California, Irvine.

Who makes Meperidine, Midazolam?

Meperidine, Midazolam is developed and marketed by University of California, Irvine (see full University of California, Irvine pipeline at /company/university-of-california-irvine).

What development phase is Meperidine, Midazolam in?

Meperidine, Midazolam is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing